References
- Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics 2021. CA Cancer J Clin 2021; 71: 7–33. doi: 10.3322/caac.21654
- Smyth EC, Lagergren J, Fitzgerald RC, Lordick F, Shah MA, Lagergren P, et al. Oesophageal cancer. Nat Rev Dis Primers 2017; 3: 17048. doi: 10.1038/nrdp.2017.48
- Arnold M, Soerjomataram I, Ferlay J, Forman D. Global incidence of oesophageal cancer by histological subtype in 2012. Gut 2015; 64: 381–7. doi: 10.1136/gutjnl-2014-308124
- Lagergren J, Smyth E, Cunningham D, Lagergren P. Oesophageal cancer. Lancet 2017; 390: 2383–96. doi: 10.1016/S0140-6736(17)31462-9
- Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson Jr JA, Al-Sarraf M, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999; 281: 1623–7. doi: 10.1001/jama.281.17.1623
- Gwynne S, Hurt C, Evans M, Holden C, Vout L, Crosby T. Definitive chemoradiation for oesophageal cancer: a standard of care in patients with non-metastatic oesophageal cancer. Clin Oncol 2011; 23: 182–8. doi: 10.1016/j.clon.2010.12.001
- Xi M, Xu C, Liao ZX, Hofstetter WL, Murphy MB, Maru DM, et al. The impact of histology on recurrence patterns in esophageal cancer treated with definitive chemoradiotherapy. Radiother Oncol 2017; 124: 318–24. doi: 10.1016/j.radonc.2017.06.019
- Sudo K, Xiao L, Wadhwa R, Shiozaki H, Elimova E, Taketa T, et al. Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer. J Clin Oncol 2014; 32: 3400–5. doi: 10.1200/JCO.2014.56.7156
- Liu SL, Luo LL, Zhao L, Zhu YJ, Liu H, Li QQ, et al. Induction chemotherapy followed by definitive chemoradiotherapy versus chemoradiotherapy alone in esophageal squamous cell carcinoma: a randomized phase II trial. Nat Commun 2021; 12: 4014. doi: 10.1038/s41467-021-24288-1
- Sun Y, Li WF, Chen NY, Zhang N, Hu GQ, Xie FY, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomized controlled trial. Lancet Oncol 2016; 17: 1509–20. doi: 10.1016/S1470-2045(16)30410-7
- Chen MQ, Lin QL, Chen YG, Guo JH, Xu BH, Tian Y. Neoadjuvant chemotherapy may not benefit esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy. J Chin Med Assoc 2017; 80: 636. doi: 10.1016/j.jcma.2017.06.014
- Luo LL, Xi M, Yang YD, Li QQ, Zhao L, Zhang P, et al. Comparative outcomes of induction chemotherapy followed by definitive chemoradiotherapy versus chemoradiotherapy alone in esophageal squamous cell carcinoma. J Cancer 2017; 8: 3441–7. doi: 10.7150/jca.21131
- Akinori M, Michitaka H, Yousuke I, Tsuyoshi K, Tairo R, Gencho K, et al. Induction chemotherapy followed by chemoradiotherapy for T4M0 esophageal cancer. Esophagus 2011; 8: 31–7. doi: 10.1007/s10388-011-0255-y
- Jin J, Liao ZX, Zhang Z, Ajani J, Swisher S, Chang JY, et al. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys 2004; 60: 427–36. doi: 10.1016/j.ijrobp.2004.03.033
- Malaisrie SC, Hofstetter WL, Correa AM, Ajani JA, Komaki RR, Rice DC, et al. The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma. Cancer 2006; 107: 967–74. doi: 10.1002/cncr.22077
- Li C, Wang X, Wang L, Chen JQ, Zhang WC, Pang QS, et al. Clinical practice and outcome of radiotherapy for advanced esophageal squamous cell carcinoma between 2002 and 2018 in China: the multi-center 3JECROG Survey. Acta Oncologica 2021; 60: 627–34. doi: 10.1080/0284186X.2021.1902564
- Lyu B, Yin YT, Zhao YL, Yang X, Gong J, Zhang M, et al. Long-term clinical outcomes and safety analysis of superficial esophageal cancer patients treated with definitive or adjuvant radiotherapy. Cancers 2022; 14: 3423. doi: 10.3390/cancers14143423
- Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228–47. doi: 10.1016/j.ejca.2008.10.026
- Wang JN, Xiao LL, Wang S, Pang QS, Wang J. Addition of induction or consolidation chemotherapy in definitive concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone for patients with unresectable esophageal cancer: a systematic review and meta-analysis. Front Oncol 2021; 11: 665231. doi: 10.3389/fonc.2021.665231
- Wu HS, Yu YL, Zheng QH, Liu TX, Wu YH, Wang ZP, et al. Benefit of chemotherapy based on platinum with definitive radiotherapy in older patients with locally advanced esophageal squamous cell carcinoma. Radiat Oncol 2021; 16: 1–14. doi: 10.1186/s13014-021-01931-1
- Hsieh JCH, Chiang PC, Hung TM, Chao YK, Kuo YC, Wen CT, et al. Definitive concurrent chemoradiotherapy with paclitaxel plus carboplatin is superior to cisplatin plus 5-fluorouracil in patients with inoperable esophageal squamous cell carcinoma using retrospective, real-world evidence. Cancer Med 2021; 10: 8300–9. doi: 10.1002/cam4.4025
- Sher DJ, Posner MR, Tishler RB, Sarlis NJ, Haddad RI, Holupka EJ, et al. Relationship between radiation treatment time and overall survival after induction chemotherapy for locally advanced head-and-neck carcinoma: a subset analysis of TAX 324. Int J Radiat Oncol Biol Phys 2011; 81: 813–8. doi: 10.1016/j.ijrobp.2010.12.005
- Cannon DM, Geye HM, Hartig GK, Traynor AM, Hoang T, McCulloch TM, et al. Increased local failure risk with prolonged radiation treatment time in head and neck cancer treated with concurrent chemotherapy. Head Neck 2014; 36: 1120–5. doi: 10.1002/hed.23419
- Xu C, Xi M, Moreno A, Shiraishi Y, Hobbs BP, Huang ML, et al. Definitive chemoradiation therapy for esophageal cancer in the elderly: clinical outcomes for patients exceeding 80 years old. Int J Radiat Oncol Biol Phys 2017; 98: 811–9. doi: 10.1016/j.ijrobp.2017.02.097
- Cai YL, Lin YX, Jiang LS, Ye H, Li FY, Cheng NS. A novel nomogram predicting distant metastasis in T1 and T2 gallbladder cancer: a SEER-based study. Int J Med Sci 2020; 17: 1704–12. doi: 10.7150/ijms.47073
- Colzani E, Johansson ALV, Liljegren A, Foukakis T, Clements M, Adolfsson J, et al. Time-dependent risk of developing distant metastasis in breast cancer patients according to treatment, age and tumour characteristics. Br J Cancer 2014; 110: 1378–84. doi: 10.1038/bjc.2014.5
- Hemminki K, Pavlidis N, Tsilidis KK, Sundquist K, Ji J. Age-dependent metastatic spread and survival: Cancer of unknown primary as a model. Sci Rep 2016; 6: 23725. doi: 10.1038/srep23725
- Kumabe A, Zenda S, Motegi A, Onozawa M, Nakamura N, Kojima T, et al. Long-term clinical results of concurrent chemoradiotherapy for patients with cervical esophageal squamous cell carcinoma. Anticancer Res 2017; 37: 5039–44. doi: 10.21873/anticanres.11919
- Minsky BD, Neuberg D, Kelsen DP, Pisansky TM, Ginsberg RJ, Pajak T, et al. Final report of Intergroup Trial 0122 (ECOG PE-289, RTOG 90-12): phase II trial of neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys 1999; 43: 517–23. doi: 10.1016/s0360-3016(98)00463-5
- Ohtsu A, Boku N, Muro K, Chin K, Muto M, Yoshida S, et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol 1999; 17: 2915–21. doi: 10.1200/JCO.1999.17.9.2915
- Shinoda M, Ando N, Kato K, Ishikura S, Kato H, Tsubosa Y, et al. Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303). Cancer Sci 2015; 106: 407–12. doi: 10.1111/cas.12622
- Chan C, Lang S, Rowbottom C, Guckenberger M, Faivre-Finn C. Intensity-modulated radiotherapy for lung cancer: current status and future developments. J Thorac Oncol 2014; 9: 1598–608. doi: 10.1097/JTO.0000000000000346